Raxibacumab, clinically designated as PAmAb ABthrax, signifies a novel treatment approach against the infection. This single immunoglobulin , developed by ProBioGen AG , uniquely binds to the protective factor of Bacillus anthracis, demonstrably preventing its capacity to trigger harm. The process of Raxibacumab involves disrupting toxin adsorpt… Read More